Close Menu

Guardant Health, a startup company formed in 2012 by two former Illumina employees, recently announced its first product — a targeted next-gen sequencing-based assay that assesses circulating tumor DNA.

The test, Guardant 360, analyzes 54 oncogenes and tumor suppressor genes. It requires a patient blood sample and uses a proprietary target capture to zero in on the specified genes. Sequencing is done on Illuumina's HiSeq 2500 and turnaround time is two weeks. The company has not yet disclosed a price for its test, which is currently available via early access.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Bloomberg reports the US Centers for Medicare & Medicaid Services sent Orig3n a letter saying it has not corrected lab issues uncovered in an earlier inspection.

In an editorial at BMJ Opinion, two genetic counselors call for an increased focus on post-test patient care.

A new survey finds people in the US are getting their COVID-19 test results back faster, but not fast enough to help some viral control measures, NPR reports.

In PLOS this week: genomic analysis of malaria parasites in Ethiopia, loci linked to childhood BMI, and more.

Oct
21
Sponsored by
Roche

Target enrichment has been a major driver behind the clinical adoption of next-generation sequencing (NGS) over the last decade because it simplifies analysis and provides a cost-effective method of massive parallel resequencing. It has not only replaced Sanger sequencing, but it is actively dispensing the need for parallel copy number variant (CNV) analysis using classic techniques.

Nov
24
Sponsored by
Illumina

Numerous companies now offer non-invasive prenatal screening (testing), many on different technology platforms.